Sung, Richard and Holman, Bennett (2022) Against Evidentiary Pluralism in Pharmaceutical Regulation. In: UNSPECIFIED.

Preview

Text PSA 2022 Sung and Holman - Against Evidentiary Pluralism in Pharmaceutical Regulation.pdf Download (171kB) | Preview

Abstract

We examine arguments for and against the use of mechanistic evidence in assessing treatment efficacy and find that advocates of EBM+ and their critics have largely been talking past each other due to difference in focus. We explore aducanumab for the treatment of Alzheimer’s disease as a case which may (eventually) speak to the role of EBM+ in pharmaceutical regulation. The case suggests the debate may be more fruitful if philosophers confine debates to particular domains of medical science and weigh in prospectively instead of relying on historical cases where outcomes are known and which are susceptible to hindsight bias.

---

Export/Citation:

EndNote | BibTeX | Dublin Core | ASCII/Text Citation (Chicago) | HTML Citation | OpenURL

Social Networking:

Share |

---

Item Type:	Conference or Workshop Item (UNSPECIFIED)
Creators:	Creators Email ORCID Sung, Richard rcdsung@gmail.com 0000-0001-8779-6256 Holman, Bennett bholman@yonsei.ac.kr 0000-0001-9038-2644
Keywords:	EBM+, clinical trials, drug regulation, commercialization
Subjects:	General Issues > Evidence Specific Sciences > Medicine General Issues > Social Epistemology of Science General Issues > Values In Science
Depositing User:	Mr. Richard Sung
Date Deposited:	12 Jul 2022 03:53
Last Modified:	12 Jul 2022 03:53
Item ID:	20874
Subjects:	General Issues > Evidence Specific Sciences > Medicine General Issues > Social Epistemology of Science General Issues > Values In Science
Date:	2022
URI:	https://philsci-archive.pitt.edu/id/eprint/20874

Monthly Views for the past 3 years

Monthly Downloads for the past 3 years

Plum Analytics

Actions (login required)

View Item